This article, published in the Washington Post focuses on new initiatives brought about via advocacy such as incentivizing pharmaceutical companies to focus on drug development for kids. It also highlights the NexTGen missionto devise new T-cell therapies for children with solid tumours such as rhabdomyosarcoma. Professor Catherine Bollard comments in the piece and organisations that NexTGen advocates have founded are referenced. Please click here to read the full article.